Under the terms of the agreement, Loxo will fund Array's preclinical research, providing access to Array's world-class discovery platform and scientists, and will be responsible for target selection and conducting clinical trials. Array is eligible to receive up to $434 million in milestone payments and to receive royalties on sales of any resulting drugs. In further consideration of the rights granted to Loxo under the agreement, Array also received shares of stock in Loxo.
I would sink more into arry , tomorrow morning you will why :)
Really thinking ARRY will be bought out sooner than later , current price 19.00 as pipeline matures and partnerships advance later in Q3-Q4 looking at 30.00 per share
A MUST take a look at GEVA's pipeline and compare it to ARRY's pipeline. ARRY should be trading in the 50.00 dollar range as of today. 200.00 as the pipeline matures